Contrasting Regeneron Pharmaceuticals (NASDAQ:REGN) and Its Rivals

Regeneron Pharmaceuticals (NASDAQ: REGN) is one of 306 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Regeneron Pharmaceuticals to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.

Institutional and Insider Ownership

67.6% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals’ peers have a beta of 5.89, suggesting that their average share price is 489% more volatile than the S&P 500.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Regeneron Pharmaceuticals $4.86 billion $895.52 million 36.74
Regeneron Pharmaceuticals Competitors $290.00 million $35.57 million 148.42

Regeneron Pharmaceuticals has higher revenue and earnings than its peers. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for Regeneron Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regeneron Pharmaceuticals 1 14 11 0 2.38
Regeneron Pharmaceuticals Competitors 790 3131 11432 227 2.71

Regeneron Pharmaceuticals currently has a consensus price target of $483.04, suggesting a potential upside of 19.41%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.40%. Given Regeneron Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Regeneron Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals 23.17% 25.73% 17.01%
Regeneron Pharmaceuticals Competitors -5,315.64% -487.41% -42.72%


Regeneron Pharmaceuticals peers beat Regeneron Pharmaceuticals on 7 of the 13 factors compared.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply